Sonde

Executive Summary

Sonde Health is a Boston-based digital health company founded in 2017 that develops AI-powered vocal biomarker technology. Its platform analyzes voice samples from everyday conversations to provide continuous, non-invasive insights into mental, cognitive, and respiratory health. By enabling early detection and risk stratification, Sonde aims to transform proactive health management for individuals and organizations. The company operates in the diagnostics category and has not disclosed funding or valuation, indicating an early-stage profile. Sonde addresses a growing demand for remote, scalable diagnostics, particularly in mental health and chronic respiratory disease. Its voice-based approach offers a unique differentiator in the digital health space. Key upcoming catalysts include FDA clearances for specific indications, strategic partnerships with healthcare systems or insurers, and clinical validation studies that could drive commercial adoption. These milestones are critical for establishing credibility and market traction.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for respiratory health monitoring60% success
• Q4 2026Strategic partnership with a major telemedicine platform50% success
• Q2 2026Publication of pivotal clinical study for depression screening70% success